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24% wanted HCPs to talk about factors besides HbA1c. Further, while 44% of HCPs 
interviewed said the easiest way to achieve control was intensifying medication, 
patient’s often associated intensification and/or complex medication regimens as 
a negative aspect of control. CONCLUSIONS: The concept of “being in control” has 
multiple meanings to patients and these definitions are often at odds with HCP 
definitions. This discordance may result in suboptimal patient-HCP interactions 
as well as contribute to physician inertia to initiate and/or intensify treatments. 
Patient education and research is needed to better understand the management 
of uncontrolled diabetes.
PDB78
AnAlyzing eq-5D in PhAse 3 clinicAl triAls of tyPe 2 DiABetes 
mellitus (t2Dm): is meAn chAnge cAPturing PAtient imPAct?
Slee A.1, Traina S.2, Neslusan C.2
1Axio Research, Seattle, WA, USA, 2Janssen Global Services, LLC, Raritan, NJ, USA
OBJECTIVES: Although literature on EQ-5D in T2DM indicates sensitivity to long-
term complications of the disease, Phase 3 trials, which by necessity are of short 
duration, have failed to detect changes in EQ-5D. The objective of this study was to 
examine if the traditional mean difference approach obscured meaningful changes 
in EQ-5D in a clinical trial of canagliflozin versus glimepiride in dual therapy with 
metformin. METHODS: Mean change in EQ-5D was calculated from baseline to 
Week 52. The empirical distribution of individual change scores was examined to 
assess how well the mean reflected individual experience. Comparisons of clinical 
and patient-reported outcomes (PROs) were performed across subgroups based 
on EQ-5D change (improve, decline, no change) to explore potential correlates of 
response. RESULTS: Mean change in EQ-5D among patients with both data points 
(N = 1,070) was 0.01 with a standard deviation of 0.2, indicating no difference from 
zero. The empirical distribution revealed that only 43.6% of patients had no change, 
while 33.4% improved and 23.0% declined. Decliners were more likely to be female 
(51.6% vs 40.5%), have a history of depression (9.3% vs 5.7%), lower baseline A1C (7.6% 
vs 7.8%), and worse baseline PROs versus those with no change. They also had more 
symptomatic hypoglycemic episodes (20.5% vs 13.7%) and poorer PRO responses. 
Improvers were more likely to be female (50.7% vs 40.5%) and to have worse PROs 
at baseline versus those with no change. They were also more likely to avoid weight 
gain (75.4% vs 69.2%) and symptomatic hypoglycemic episodes (84.5% vs 66.7%), as 
well as report greater improvements in PROs. CONCLUSIONS: This analysis sug-
gests that the mean change in EQ-5D may not sufficiently reflect patient experience 
in clinical trials of T2DM, and that patient-relevant factors such as weight change 
and symptomatic hypoglycemia are likely to be important predictors of response.
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OBJECTIVES: Medication adherence in patients with metabolic syndrome is vital 
for disease control. It is important to recognize patients’ barriers of adherence to 
improve outcomes. The objective of the study is to assess how patient self-reported 
barriers to adherence affect the pill counts of their medications and patient adher-
ence. METHODS: Appointments were held with 30 adult, English speaking patients, 
having type II diabetes, hypertension, hyperlipidemia, at least one oral medication 
for each disease state, and a minimum of five oral prescription medications. Pill 
counts were conducted, and patients were verbally asked seven questions targeting 
adherence barriers with responses assessed using a 4-point Likert-type scale from 
(1) Disagree completely to (4) Agree completely. Some questions included, “In the 
past two weeks, I forgot to take my medication at least once,” “I believe medicines do 
more harm than good.” Patients were placed into seven groups based on responses. 
Patients reporting more than one barrier were placed in multiple groups and pill 
counts of each group were averaged. Groups were analyzed to determine how barri-
ers influence pill count scores. Groups with pill count scores > .80 were determined 
to be adherent. RESULTS: The barrier, “forgot to take my medication,” was the most 
acknowledged of all barriers (N= 12) with a pill count score of .59, conversely (N= 18), 
.52. The least acknowledged barrier “I stop my medication if I do not feel it working” 
(N= 1) had a score of .94, conversely (N= 28), .52. Eight patients did not acknowledge 
any barriers with a pill count score of .44. CONCLUSIONS: Patients’ scores reflected 
that although patients did not report experiencing a barrier, they were non-adherent 
to their medications. Patients may misreport barriers, or not realize the barriers 
affecting them. Healthcare professionals must improve communication targeting 
adherence barriers specific to the patient to improve health outcomes.
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OBJECTIVES: Children with Growth Hormone Deficiency (GHD) can experience 
physical symptoms and limitations as well as a range of social and emotional prob-
lems. Unfortunately, no GHD specific measures exist to assess these impacts. This 
qualitative study identified key symptoms/impacts of GHD disease and treatment 
in order to support the development of a patient-reported outcome measure (PRO) 
for children ages 10-13 and an observer-reported outcome measure (ObsRO) for 
parents/guardians of younger children. METHODS: Focus groups and interviews 
were conducted with 39 children (age 8 -12) with GHD and 34 parents of children (age 
4 to 12) in 3 countries (Germany, UK US). All interviews were transcribed, analyzed, 
and coded thematically using adapted grounded theory to determine overarching 
themes and concepts. Based on the analysis, expert interviews and literature review, 
a conceptual model of GHD impacts was developed. RESULTS: Qualitative analy-
sis found saturation of concepts was reached with 3 domains of impact: Physical, 
Social, and Emotional. Sub-concepts included strength/endurance (48%), appetite 
age, sex, ethnicity, and smartphone ownership. Approximately 67% of patients 
had a computer at home. More than 65% reported interest in using electronic 
methods to interact more with their physician between visits to help manage 
and treat their disease. Patients reported that they were more likely to speak 
with their physician (46%), report disease symptoms (38%), report on their quality 
of life (37%), and take medication (32%) if they had more knowledge about their 
disease. When asked about the most effective way of improving their health and 
managing their disease, 32% responded “increasing communication and interac-
tions between my physician and me”; another 31% were interested in monitoring 
their disease, symptoms, and/or medications electronically so that their physician 
could see their health status in real time. Patients preferred electronic methods of 
managing their disease, including email and text message communications with 
their healthcare provider (73%), clinical visit scheduling via smartphone (76%), 
and medication reminders via smartphone (83%). CONCLUSIONS: Patients are 
interested in using electronic methods to increase communication with their phy-
sician and manage their disease. Possible opportunities for addressing this need 
include educational smartphone apps, medication reminders via text messaging, 
and clinic visit scheduling via smartphone. Providers should consider engaging 
patients with e-clinical technology to increase patient-physician communication 
and for the ultimate goal of improved healthcare.
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OBJECTIVES: To assess the preferences of Spanish and Portuguese patients and 
physicians regarding T2DM treatments and the monthly willingness to pay (WTP) 
for gaining benefits or avoiding side effects. METHODS: An observational, multi-
center, exploratory study focused on routine clinical practice in Spain and Portugal. 
Professionals were recruited from diverse hospitals and outpatient’s clinics while 
patients were recruited from 11 centers operating in the public healthcare system 
in different autonomous communities in Spain and in Portugal. Preferences were 
measured via a discrete choice experiment. Data was analyzed using a conditional 
logit model. RESULTS: 221 professionals from the Spanish and Portuguese NHS [62% 
female; mean age 41.9 (SD: 10.5); 33.5% endocrinologists, 66.5% GP] and 330 patients 
[49.7% female; mean age 62.4 (10.1), mean disease duration 13.98 (8.22) years, mean 
BMI 32.50 (6.82), 41.8% received oral + injected medication, 40.3% received oral and 
17.6% injected treatments] participated. Professionals placed the most value on 
avoiding one hypoglycemia per week [WTP: 287.18€ (95% CI: 160.31 - 1,387.21)], 
followed by avoid gaining 3 Kg/6 months and decreasing cardiovascular risk [WTP: 
166.87€ (88.63 - 843.09) and 154.30€ (98.13 - 434.19), respectively]. Patients placed 
the most value on the weight attribute [WTP: 68.14€ (54.55 - 85.08) to avoid gaining 
3 kg/6 months], followed by avoiding one hypoglycemic event per month [WTP: 
54.80€ (23.29 - 82.26)]. Professionals and patients were willing to pay 125.92€ (73.30 
– 622.75) and 24.28€ (18.41 – 30.31), respectively, to avoid increasing 1% of HbA1c 
and 143.30€ (73.39 – 543.62) and 42.74€ (23.89 – 61.77), respectively, for avoiding 
nausea. CONCLUSIONS: Both patients and professionals in Spain and Portugal are 
willing to pay for the health benefits associated with improved diabetes treatment, 
being the most important avoiding hypoglycemia and gaining weight. Decrease in 
cardiovascular risk and weight reduction became the third most valued attributes 
for professionals and patients, respectively.
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OBJECTIVES: This qualitative study was conducted to address critical gaps on 
how type-2 diabetes patients using basal insulin understand the concept of their 
diabetes “being in control”. METHODS: Forty-nine type-2 diabetes patients on 
basal insulin (focus groups N= 45, individually N= 4) and 9 health care provid-
ers (HCPs), were interviewed in Sweden, Denmark, UK, and Switzerland. Patients 
were asked about their understanding of control, obstacles to achieving and how 
their understanding of control compared with their HCP. The interviews were 
transcribed, coded and qualitatively analyzed, based on grounded theory, to iden-
tify and quantify emerging themes. RESULTS: The mean age of patients was 64 
(range 28-83) with approximately 50% considering their diabetes out of control. 
In contrast to the accepted medical definition of control based on HbA1c (average 
plasma glucose value), 58% of patients associated diabetes control with factors 
other than HbA1c; 80% associated control with daily or hourly meter readings; 76% 
day-to-day feelings; 40% sugar fluctuations, and 38% with limitations in daily life. 
Major obstacles to control were: managing diet/appetite: 87%; inadequate educa-
tion from HCPs: 71%; lack of social support and schedule and lifestyle issues: 69%. 
Only 42% of patients mentioned medication regimen as affecting control. Twenty-
seven percent felt they had different definitions of control than their HCPs, and 
